Blog

Choosing a weight-loss medication can feel overwhelming, especially when you keep hearing about Mounjaro and Wegovy on social media. Both are injectable prescription medicines that can help eligible adults lose weight, reduce hunger, and manage food cravings. However, they work differently, and the right option depends on more than how many kilograms you want to lose.

You may be wondering: Will Mounjaro help me lose weight faster? Is Wegovy safer? What happens if I stop the injections? Can I use these medicines if I have PCOS, diabetes, or thyroid problems? And how much will the treatment cost over several months?

These are important questions to ask before starting any medical weight-loss programme. At Influennz Clinic, weight management should begin with an assessment of your health, weight history, eating patterns, and treatment goals, not simply a choice between two popular injections. This guide explains the differences between Mounjaro and Wegovy, the clinical evidence behind their results, possible side effects, long-term considerations, and the questions you should discuss with your doctor.

Mounjaro vs Wegovy: Quick Comparison

Mounjaro and Wegovy are both given as once-weekly injections, but they contain different active ingredients and act on different hormone pathways.

The short answer: Mounjaro (tirzepatide) produced greater average weight loss than Wegovy (semaglutide 2.4 mg) in a direct clinical comparison involving adults with obesity who did not have diabetes. However, the medicine that works best for an individual also depends on medical history, tolerability, availability, affordability, and the ability to continue treatment safely. Importantly, the comparison above refers to the studied weight-management regimens. Brand indications, approved doses, and availability can vary by country.

What Is Mounjaro and How Does It Help With Weight Loss?

Mounjaro contains tirzepatide, a prescription medicine that activates two hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). These hormone pathways help regulate blood glucose, appetite, and the body’s response to food. By acting on both pathways, tirzepatide can help some patients feel satisfied with smaller portions and experience less persistent hunger.

How does Mounjaro help reduce body weight?

Mounjaro may help by:

• Reducing appetite and the urge to eat between meals.
• Increasing feelings of fullness after eating.
• Helping some people feel satisfied with smaller portions.
• Slowing stomach emptying, particularly during the early stages of treatment.
• Improving blood glucose regulation in appropriate patients.

For someone who feels hungry soon after eating, frequently snacks despite trying to follow a diet, or struggles to maintain a calorie deficit, these effects may make a structured weight-management plan easier to follow. However, Mounjaro is not a fat-burning injection that directly melts body fat. Weight reduction generally occurs because the medicine changes appetite and food intake, alongside other metabolic effects.

How much weight can you lose with Mounjaro?

The amount of weight lost varies according to the dose, treatment duration, baseline weight, health conditions, lifestyle, and individual response. In the 72-week SURMOUNT-5 clinical trial, adults with obesity or overweight with a weight-related health condition, but without diabetes, received tirzepatide or semaglutide alongside lifestyle support.

The average weight reduction with tirzepatide was approximately 20.2% of starting body weight under the trial’s primary analysis. For example, if a person weighs 100 kg, a 20.2% reduction would equal approximately 20.2 kg. This is an illustration of the trial average, not a prediction of what any individual will lose. Some participants lost more, some lost less, and individual results cannot be guaranteed.

Is Mounjaro only for people with diabetes?

No. Tirzepatide has different approved uses depending on the country and product. Mounjaro is used for type 2 diabetes in many markets and may also be approved for weight management in certain countries, including India, subject to the applicable product label.

A person does not necessarily need diabetes to qualify for a weight-management medicine. However, the doctor must establish whether the patient meets the relevant eligibility criteria and whether the treatment is appropriate.

Read more about weight-loss treatment and medical weight management at Influennz Clinic.

What Is Wegovy and How Does It Help With Weight Loss?

Wegovy contains semaglutide, a GLP-1 receptor agonist. It mimics the action of a naturally occurring hormone involved in appetite regulation and blood glucose control. It helps eligible patients feel fuller, reduces hunger, and may decrease the amount of food they eat.

How does Wegovy work?

Wegovy may help patients by:

• Reducing hunger and appetite.
• Increasing fullness after meals.
• Helping reduce food intake and frequent snacking.
• Supporting blood glucose regulation.
• Making it easier for some patients to maintain long-term dietary changes.

Wegovy is administered once weekly by injection for its injectable weight-management formulation. Treatment typically begins at a lower dose and increases gradually according to the prescribed schedule to improve tolerability.

How much weight can you lose with Wegovy?

In the STEP 1 clinical trial, adults with overweight or obesity without diabetes who received semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 14.9% of their initial body weight over 68 weeks.

This result comes from a different trial than the Mounjaro comparison, so the percentages should not be compared directly as if the participants and study conditions were identical. The more useful direct comparison is the SURMOUNT-5 trial, discussed below.

Is Wegovy the same as Ozempic?

Both contain semaglutide, but they are different branded products with different approved indications and dosing regimens in many markets.

Wegovy is specifically associated with chronic weight management in countries where that indication is approved. Ozempic is primarily indicated for type 2 diabetes in many markets.

The fact that two medicines contain the same active ingredient does not mean that their brands, doses, or approved uses are interchangeable. A doctor should select the appropriate product based on the patient’s medical needs and the local prescribing information.

Mounjaro vs Wegovy: Which One Produces Greater Weight Loss?

This is one of the most important questions for anyone comparing these medicines.

Earlier studies showed that both tirzepatide and semaglutide can produce substantial weight reduction. However, differences between separate studies made it difficult to determine which treatment was more effective.

The SURMOUNT-5 trial provided a direct comparison.

What did the SURMOUNT-5 study find?

The phase 3b trial included 751 adults with obesity or overweight with at least one weight-related health condition who did not have diabetes. Participants received the maximum tolerated doses of tirzepatide or injectable semaglutide 2.4 mg, alongside lifestyle support, for 72 weeks.

Source: SURMOUNT-5, published in The New England Journal of Medicine in 2025.

The study found that tirzepatide produced significantly greater average weight loss than semaglutide 2.4 mg in this population. The trial was open-label, and the results should not be interpreted as a guarantee for an individual patient.

What do these numbers mean in everyday life?

Imagine two people who each weigh 100 kg before treatment.

• A 20.2% reduction would mean approximately 20.2 kg lost.
• A 13.7% reduction would mean approximately 13.7 kg lost.

The difference between these illustrative averages is 6.5 kg.

However, these figures are not a head-to-head prediction for two specific people. Actual outcomes can differ considerably, and results may be different in people with type 2 diabetes or other health conditions.

What is the conclusion? If the main consideration is average weight loss based on this particular head-to-head trial, tirzepatide had the advantage. That does not automatically make it the best choice for every patient.

Mounjaro vs Wegovy: Which One Is Better for Belly Fat?

Many patients are less concerned about their overall weight than about abdominal fat. They may have a relatively stable weight but notice an increasing waist circumference, difficulty fitting into clothes, or fat around the abdomen despite exercising. Neither medicine selectively targets belly fat. Both can reduce overall body weight, and waist circumference may decrease as total body fat declines.

In SURMOUNT-5, tirzepatide produced a greater average reduction in waist circumference than semaglutide 2.4 mg.

However, it is important to understand the difference between:

• Subcutaneous fat: Fat stored beneath the skin, which can be pinched.
• Visceral fat: Fat stored deeper in the abdomen around internal organs.
• Bloating: Abdominal distension that may relate to digestion, constipation, or other causes rather than fat.

A larger abdomen is not always caused by excess fat. A clinician may need to consider waist measurements, weight history, metabolic health, and other symptoms before recommending treatment. For people with excess abdominal fat, the aim should be to improve overall health and body composition rather than simply chase a smaller waist.

Which Is Better for People With PCOS, Insulin Resistance, or Type 2 Diabetes?

Patients with polycystic ovary syndrome (PCOS), insulin resistance, or type 2 diabetes often have different treatment priorities from someone seeking weight reduction alone.

Mounjaro vs Wegovy for PCOS

PCOS can be associated with insulin resistance, irregular periods, acne, unwanted hair growth, and difficulty managing weight. However, not every person with PCOS has insulin resistance or obesity.

Neither Mounjaro nor Wegovy should automatically be considered the first or only treatment for PCOS. Evidence for their use specifically to treat PCOS is less established than the evidence for their approved indications in weight management or diabetes.

Depending on the individual, a clinician may consider nutrition, physical activity, sleep, metabolic screening, and appropriate medicines. Weight-management injections may be considered for eligible patients when clinically appropriate.

People who may become pregnant need to discuss pregnancy planning and contraception before starting treatment.

Mounjaro vs Wegovy for insulin resistance

Both medicines can influence glucose regulation and appetite. Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide activates GLP-1 receptors.

The choice should not be based on the assumption that one mechanism will necessarily work better for every patient with insulin resistance. The patient’s glucose results, weight-related conditions, medical history, and approved treatment options all matter.

What if you have type 2 diabetes?

Both tirzepatide and semaglutide have diabetes-related uses, depending on the product and country. Weight-loss results can differ in people with diabetes compared with people without diabetes.

If you take insulin or a sulfonylurea, your doctor may need to adjust your diabetes treatment and monitor your blood glucose because the combination can increase the risk of low blood sugar.

Do not start, stop, or change diabetes medicines on your own.

Side Effects: Is Mounjaro Safer Than Wegovy?

Both medicines can cause gastrointestinal side effects. The fact that one produces greater average weight loss does not establish that it is safer or easier to tolerate for every individual.

Common side effects of Mounjaro and Wegovy

Possible side effects include:

• Nausea, especially after starting treatment or increasing the dose.
• Vomiting.
• Diarrhoea.
• Constipation.
• Abdominal discomfort or pain.
• Bloating, indigestion, or belching.
• Reduced appetite.

Many gastrointestinal symptoms are mild to moderate and may improve as the body adjusts, but some people experience persistent symptoms that require medical review.

Why do some patients struggle during the first few weeks?

A common concern is feeling nauseated after meals, being unable to eat normally, or experiencing constipation after increasing the dose. These symptoms may occur because the medicines influence appetite and stomach emptying. Large meals, eating quickly, or eating beyond fullness may worsen discomfort for some patients.

A clinician may recommend eating smaller portions, eating slowly, staying hydrated, and avoiding foods that trigger symptoms. Persistent symptoms should not simply be ignored. Dose escalation should follow the prescribed schedule. Increasing the dose faster to lose weight more quickly can increase the risk of adverse effects.

Serious risks you should know about

Although not everyone experiences serious problems, both medicines have important warnings and precautions.

These may include:

• Pancreatitis: Persistent, severe abdominal pain, sometimes radiating to the back, requires urgent medical assessment.
• Gallbladder problems: Gallstones or gallbladder inflammation can occur, including in the context of substantial weight loss.
• Dehydration and kidney problems: Severe vomiting or diarrhoea can cause fluid loss and potentially affect kidney function.
• Severe gastrointestinal problems: These medicines may not be suitable for people with certain serious stomach-emptying disorders.
• Low blood sugar: The risk can increase when used with insulin or certain other diabetes medicines.
• Allergic reactions: Swelling of the face or throat, breathing difficulty, or a severe allergic reaction requires emergency care.

Seek urgent medical attention for severe or persistent abdominal pain, repeated vomiting with inability to keep fluids down, or signs of a serious allergic reaction.

What about thyroid cancer warnings?

The prescribing information for these medicines includes warnings related to thyroid C-cell tumours based on animal studies. In the United States, certain products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). The precise wording and contraindications depend on the local product label. Tell your doctor about any relevant personal or family medical history before treatment.

Can you use Mounjaro or Wegovy during pregnancy?

These medicines are not intended for weight-loss treatment during pregnancy. If you are pregnant, planning pregnancy, or breastfeeding, discuss this with your doctor before starting treatment.

Semaglutide generally needs to be discontinued at least two months before a planned pregnancy according to its prescribing information. Tirzepatide also requires pregnancy-related precautions; discuss the appropriate discontinuation plan with your prescriber.

Tirzepatide can reduce the reliability of oral hormonal contraceptives during treatment initiation and after dose increases. Ask your clinician about the additional contraceptive precautions specified in the prescribing information.

How Long Does Mounjaro or Wegovy Take to Work?

Patients often expect to see a visible difference within the first few weeks. When the scale moves slowly, they may worry that the medicine is not working.

Both treatments use gradual dose escalation to improve tolerability. The starting dose is not necessarily the dose at which the full weight-management effect is expected.

Some people notice reduced hunger or smaller portion sizes early in treatment. Meaningful weight changes usually develop over time, and the rate varies from person to person.

What if you do not lose weight in the first month?

A slow start does not automatically mean treatment failure.

Your doctor may review:

• Whether you are still on an introductory dose.
• How consistently the medicine is being used.
• Your eating pattern, protein intake, and physical activity.
• Constipation, fluid retention, or other factors affecting scale weight.
• Other medicines or medical conditions that influence weight.
• Whether the dose and treatment plan are appropriate.

Do not increase the dose yourself or combine medicines to accelerate results.

What if the weight-loss effect slows down?

Weight loss is rarely perfectly linear. It is normal for the rate of weight reduction to change as body weight falls and the body adapts.

A plateau is a reason to review the overall plan, not automatically to increase the dose. The clinician may assess adherence, treatment tolerability, nutrition, sleep, activity, and the expected response at the current stage.

What Happens When You Stop Mounjaro or Wegovy?

This is one of the most important questions to ask before beginning long-term weight management. Many patients worry that they will regain all the weight they lose once they stop injections. Weight regain is a real possibility because the biological signals that regulate hunger and appetite do not necessarily disappear when treatment ends.

In the STEP 1 extension study, participants who stopped semaglutide regained a substantial proportion of their previously lost weight during the following year. Other research has also demonstrated that maintaining weight loss after discontinuing these medicines can be challenging.

This does not mean everyone will regain the same amount of weight. It means that weight maintenance should be discussed before treatment begins, rather than only when someone is ready to stop.

How can you reduce the risk of weight regain?

A sustainable plan may include:

• A balanced eating pattern that can be maintained long term.
• Adequate protein and nutrient intake.
• Resistance exercise to help preserve muscle mass.
• Regular physical activity.
• Consistent sleep and practical stress-management strategies.
• Ongoing medical follow-up.
• A clinician-guided plan for continuing, adjusting, or discontinuing treatment.

Some patients may require longer-term pharmacological management. The decision depends on clinical response, risks, treatment goals, and the relevant prescribing guidance. Do not stop or restart treatment without discussing the plan with your doctor.

Can You Switch From Mounjaro to Wegovy or From Wegovy to Mounjaro?

Switching may be considered when a patient experiences inadequate response, troublesome side effects, affordability concerns, supply problems, or a change in clinical circumstances. However, switching is not as simple as substituting one injection for another at the same dose.

The medicines have different dosing schedules, and there is no direct milligram-for-milligram equivalence. Your doctor should determine the timing, starting dose, monitoring plan, and whether any gap between treatments is appropriate. Never use Mounjaro and Wegovy together unless a qualified prescriber has specifically assessed the situation and determined an appropriate plan. Combining tirzepatide with another GLP-1 receptor agonist is generally not recommended.

If one medicine seems less effective, first review your treatment duration, prescribed dose, adherence, eating pattern, and any medical factors that could affect progress.

Mounjaro vs Wegovy: Which Is More Affordable in India?

For many patients, the practical question is not simply which medicine works better. It is which treatment they can access, tolerate, and sustain financially. The total cost may include the medicine, medical consultations, follow-up visits, any recommended investigations, and ongoing nutrition or lifestyle support.

Prices can vary by dose, pack size, pharmacy, availability, and changes in local pricing. Therefore, it is better to obtain a current quotation for the exact prescribed product rather than rely on a single online price.

Questions to ask before comparing costs

1. What is the current cost of the prescribed dose?
2. How often will follow-up visits be needed?
3. What is the expected treatment and monitoring plan?
4. What happens financially if the dose changes?
5. How will treatment and weight maintenance be managed over the longer term?

A medicine that costs less initially may not be the most suitable choice if it is poorly tolerated or inappropriate for the patient’s medical needs. Equally, a more expensive medicine should not be chosen solely because it may produce greater average weight loss in a clinical trial.

Do not purchase prescription injections from unverified sellers or use products with uncertain storage conditions.

Who May Be a Suitable Candidate for Medical Weight-Loss Treatment?

Prescription weight-management medicines are not intended for everyone who wants to lose a few kilograms.

Eligibility depends on the medicine’s local approval, body mass index (BMI), weight-related medical conditions, contraindications, and an individual clinical assessment.

In many weight-management guidelines, medication may be considered for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related condition. The exact criteria and product indications must be checked against applicable local guidance.

A doctor may assess:

• Current weight, height, BMI, and waist circumference.
• Previous attempts at weight management and weight fluctuations.
• Blood pressure and relevant metabolic risk factors.
• Blood glucose or HbA1c when indicated.
• Other medicines and medical conditions.
• History of pancreatitis, gallbladder disease, or significant digestive problems.
• Pregnancy plans and relevant family medical history.
• Whether the patient can follow up and sustain the recommended treatment plan.

People with eating disorders, significant nutritional deficiencies, or other complex medical concerns may need a more specialised assessment before considering weight-loss medication.

What if you only want to lose 5–7 kg?

A modest weight-loss goal does not automatically justify an injectable medicine.

The clinician should assess whether medication is indicated, whether the expected benefits outweigh the risks, and whether a structured nutrition and activity programme would be more appropriate.

The goal is not to prescribe the strongest medicine available. It is to select an evidence-based treatment that is appropriate for the person’s health.

Why Medical Supervision Matters During Weight-Loss Injections

Weight-loss injections can reduce appetite substantially. Without an appropriate nutrition plan, some patients may unintentionally eat too little, miss essential nutrients, or lose muscle along with body fat.

This is particularly relevant when patients focus only on the number on the scale.

A supervised programme should consider:

Nutrition: Adequate protein, fibre, fluids, and overall energy intake, adjusted to the patient’s needs and tolerability.

Physical activity: A realistic combination of aerobic activity and resistance training, where medically appropriate.

Progress monitoring: Changes in weight, waist circumference, symptoms, and relevant health measurements.

Medication review: Dose escalation, adverse effects, other medicines, and whether the treatment remains appropriate.

Long-term planning: Maintenance strategies and decisions about continuing or changing therapy.

The aim is to improve health and support sustainable weight management—not simply achieve the fastest possible weight reduction.

Mounjaro vs Wegovy: Which One Should You Choose?

There is no single answer that fits everyone, but the evidence and clinical considerations can help you prepare for an informed decision.

Mounjaro may be worth discussing if:

• You meet the eligibility criteria for a tirzepatide-based treatment.
• Your priority is substantial weight reduction and you understand the limitations of average trial results.
• You and your clinician determine that its risks, dosing, cost, and availability are appropriate for you.

Wegovy may be worth discussing if:

• You meet the eligibility criteria for semaglutide-based weight management.
• Its approved indications and clinical profile fit your medical needs.
• Your clinician considers it an appropriate option based on your health history and treatment goals.

Either medicine may be inappropriate if:

• You have a relevant contraindication or a medical condition that makes treatment unsafe.
• You are pregnant or planning pregnancy without an appropriate medical plan.
• You are seeking a rapid cosmetic change without an appropriate clinical indication.
• You cannot access safe prescribing, follow-up, or a reliable supply of the medicine.

A practical decision checklist

Before making a decision, ask your doctor:

• Am I medically eligible for either medicine?
• What is a realistic weight-loss target for my starting weight and health status?
• Which risks matter most in my case?
• How will side effects be managed?
• What will treatment cost at the likely prescribed dose?
• How will we evaluate whether the medicine is working?
• What is the long-term plan if I reach my target weight or stop treatment?

These questions are often more useful than choosing a medicine based on social media testimonials or another person’s results.

Medical Weight Management at Influennz Clinic, Delhi

If you have struggled with repeated dieting, persistent hunger, weight regain, or difficulty maintaining lifestyle changes, a medical consultation can help clarify the options available to you.

At Influennz Clinic, Hauz Khas, South Delhi, a consultation can be used to discuss your weight history, health concerns, suitability for medical treatment, and the role of nutrition and lifestyle measures in a long-term plan.

The appropriate approach may involve lifestyle management, medication when indicated, or further evaluation of underlying health factors. Not everyone requires an injectable medicine, and no specific weight-loss result can be guaranteed.

To learn more about the clinic and its services, visit the Influennz Clinic website.

Before your consultation, consider bringing a list of your current medicines, any recent blood tests, your weight history, and details of previous weight-loss attempts. This information can help the clinician assess your needs more effectively.

Medical disclaimer: This article is for educational purposes only and does not replace an individual medical consultation, diagnosis, or prescription. Do not start, stop, combine, or change the dose of weight-loss medicines without guidance from a qualified healthcare professional.

Frequently Asked Questions

1. Is Mounjaro more effective than Wegovy for weight loss?

In the 72-week SURMOUNT-5 trial, tirzepatide produced an average weight reduction of 20.2%, compared with 13.7% with semaglutide 2.4 mg, in adults with obesity or overweight with a weight-related condition who did not have diabetes. Individual results can differ.

2. How much weight can I lose in one month with Mounjaro?

There is no reliable single figure for everyone. Weight changes depend on the starting dose, treatment stage, appetite response, eating pattern, activity, and individual health factors. Early treatment is generally focused on gradual dose escalation and tolerability rather than achieving a fixed monthly target.

3. How much weight can I lose in one month with Wegovy?

The amount varies between patients. Some notice appetite changes early, while measurable weight reduction develops over time. A clinician should assess progress over an appropriate period rather than judging success from a single month’s weight change.

4. Which injection works faster, Mounjaro or Wegovy?

There is no guaranteed timeline for either medicine. Although tirzepatide produced greater average weight loss in the direct comparison trial, that does not establish that every patient will lose weight faster with it in the first few weeks.

5. Can I take Mounjaro if I do not have diabetes?

Potentially, if the product is approved for weight management in your location and you meet the relevant eligibility criteria. A medical assessment is necessary before treatment.

6. Is Wegovy only for people with diabetes?

No. Wegovy is a weight-management medicine in countries where that indication is approved. Eligibility depends on the local product label and the patient’s clinical circumstances.

7. Can Mounjaro or Wegovy help with PCOS-related weight gain?

They may be considered for eligible patients who need medical weight management, but neither should be assumed to be a specific treatment for every PCOS symptom. The clinician should assess metabolic health, reproductive plans, and other treatment options.

8. Will I regain weight after stopping Mounjaro or Wegovy?

Weight regain is possible after discontinuation because appetite and other biological drivers of weight can return. A long-term maintenance plan is important, and stopping treatment should be discussed with your clinician.

9. Can I switch from Wegovy to Mounjaro if I am not losing weight?

A switch may be appropriate in selected cases, but it requires a prescriber-led plan. Your doctor should first assess treatment duration, dose, adherence, tolerability, and other factors that may explain your response.

10. Are Mounjaro and Wegovy safe for long-term use?

Their benefits and risks must be evaluated for the individual patient. Treatment duration depends on the indication, local prescribing guidance, clinical response, tolerability, and ongoing medical review. Neither medicine should be treated as a risk-free or purely cosmetic intervention.

11. Can I use Mounjaro or Wegovy with insulin?

Sometimes, under medical supervision, but the combination may increase the risk of low blood sugar. Insulin or other diabetes medicines may require adjustment by the prescribing clinician.

12. Do Mounjaro and Wegovy burn fat directly?

No. They influence appetite, food intake, and metabolic pathways that can support weight reduction. The reduction in body fat generally occurs as part of overall weight loss; neither medicine selectively burns fat from the abdomen or another specific area.

13. Which is better for long-term weight maintenance?

Both can support weight management during treatment, but long-term results depend on individual response, ongoing treatment where appropriate, nutrition, physical activity, and follow-up. There is no universal answer about which will maintain weight loss better for every patient.

14. Can I buy Mounjaro or Wegovy without a prescription?

These are prescription medicines and should be used under appropriate medical supervision. Avoid unverified online sellers, products with uncertain authenticity, and dosing advice from non-medical sources.

15. What is the most important thing to consider before starting a weight-loss injection?

Consider whether you are medically eligible, the potential benefits and risks, how the medicine will be monitored, whether you can tolerate and afford treatment, and how weight maintenance will be managed in the longer term.

Final Verdict: Mounjaro or Wegovy?

The clinical evidence gives tirzepatide an advantage for average weight reduction over semaglutide 2.4 mg in the SURMOUNT-5 head-to-head trial. Both medicines can nevertheless be effective options for eligible patients, and neither guarantees a particular result.

The right decision depends on your health, treatment goals, risk factors, budget, and the advice of a qualified prescriber. It should also include a plan for nutrition, physical activity, follow-up, and maintaining progress over time.

If you are considering medical weight management in South Delhi, arrange a consultation at Influennz Clinic to discuss your options and determine whether prescription treatment is appropriate for you.